Project Details
Description
A 6-month phase 3, multicenter, prospective, randomized, double-blind, vehicle-controlled study, to evaluate the efficacy and safety of topically applied clascoterone (cortexolone 17a-propionate) solution for the treatment of androgenetic alopecia in mal
| Status | Active |
|---|---|
| Effective start/end date | 4/10/23 → 4/30/28 |
Funding
- CASSIOPEA, S.P.A.
Fingerprint
Explore the research topics touched on by this project. These labels are generated based on the underlying awards/grants. Together they form a unique fingerprint.